Microbiology Characteristics Among Cystic Fibrosis Patients in Western Romania

Open access

Abstract

Background: Pulmonary infectious inflammation is a major cause of decline in lung function in patients with cystic fibrosis (CF) marked by exacerbations, consequently, slowing evolution of lung disease is a primary aim in CF management. The objective of the study was to analyze the microbiological spectrum from epidemiological point of view in our patients. Methods: An observational, cross-sectional transversal study including fifty-seven patients evaluated the prevalence of CF-related microbes in the study group and their pulmonary status. Results: The most frequent microorganism found in our group, regardless age, was Staphyloccocus aureus, closely followed by Pseudomonas aeruginosa. Bacillus tuberculosis was a rare germ, despite the important frequency in our country. The microbes frequency was different with age groups, thus 3.5% of 1-3 years old children had the methicillin sen sitive Staphylococcus aureus (MSSA) strain, while for the 6-12 years group, Pseudomonas aeruginosa was found in an equal percentage of 14% with MSSA. Pseudomonas prevalence was found in 14.0% of adults and the combined infections were diagnosed in about a fifth of our patients. Conclusions: We concluded that the percentage of respiratory infections with redoubtable microbes is relatively moderate. The presence of underweight among CF patients with severe mutations are risk factor for a worse outcome and measures should be instituted.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1 Rowe SM Miller S Sorscher E. J Cystic fibrosis. N Engl J Med 2005;352(19):1992- 2001

  • 2. Farrell PM Rosenstein BJ White TB Accurso FJ Castellani C Cutting GR et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-14

  • 3. Castellani C Quinzii C Altieri S Mastella G Assael BM. A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes. Genet Test 2001;5:249-254

  • 4. Ciuca IM Pop LL Rogobete AF Onet DF Horhat FG. Genetic expression in cystic fibrosis related bone disease. An observational transversal cross-sectional study. Clin Lab 2016;62(9):1725-1730

  • 5. Kerem E Viviani L Zolin A Macneill S Hatziagorou E et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the data of the ECFS Patient Registry. Eur Respir J 2014;43(1):125-133

  • 6. Ramsay KA Sandhu H Geake JB Ballard E O’Rourke P Wainwright CE et al. The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis. J Cyst Fibros 2017;16(1):70-77

  • 7. Ciofu O Mandsberg LF Wang H Høiby N. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. FEMS Immunology & Medical Microbiology 2012;65:215-225

  • 8. Goss CH Muhlebach MS. Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros 2011;10:298-306

  • 9. Proesmans M Balinska-Miskiewicz W Dupont L et al. Evaluating the “Leeds criteria” for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir J 2006;27(5):937-43

  • 10. Lee TWR Brownlee KG Convay SP Denton M Littlewood JM. Evaluation of a new definition of chronic P. aeruginosa infection in cystic fibrosis. J Cyst Fibros 2003;2:29- 34

  • 11. Tiddens HAWM Donaldson SH Rosenfeld M Paré PD. Cystic fibrosis lung disease starts in the small airways: Can we treat it more effectively? Pediatr Pulmonol 2010;45:107-117

  • 12. Farrell PM Rosenstein BJ White TB et al. Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report. J Pediatr 2008;153(2):S4-S14.

  • 13. Popa I Pop L Popa Z Cîlt C. Ghid de management în Mucoviscidoză-Fibroza Chistică Editura Brumar 2006;9-71

  • 14. McKone E Emerson SS Edwards KL et al. Effect of genotype on phenotype and mortality in cystic fibrosis: retrospective cohort study. Lancet 2003;361:1671-1676.

  • 15. Smyth AR Bell SC Bojcin S et al. European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros 2014;13(1):S23-S42.

  • 16. Miller MR Hankinson J Brusasco V et al. Standardisation of spirometry. Eur Respir J 2005;26:319-338

  • 17. Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2007;13:529-536.

  • 18. Moran A Brunzell C Cohen RC et al. CFRD Guidelines Committee Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33:2697-270

  • 19. Ciuca IM Pop L Ranetti AL Popescu I Almajan- Guta B Malita IM. Ursodeoxicholic acid effects on cystic fibrosis liver disease. Farmacia 2015;63(4):543-547

  • 20. Milla CE. Association of nutritional status and pulmonary function in children with cystic fibrosis. Curr Opin Pulm Med 2004;10:505-509

  • 21. Turck D Braegger CP Colombo C et al. ESPENESPGHAN-ECFS guidelines on nutrition care for infants. Clin Nutr 2016;35(3):557-77

  • 22. Tamas l Popa I Pop L Anghel A Popa Z Marian C. Genetic analysis of CFTR mutations in cystic fibrosis patients from Romania. Timisoara Medical Journal 2006;56(1):23-27

  • 23. Debray D Kelly D Houwen R Strandvik B Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis- associated liver disease. J Cyst Fibros 2011;10(2):S29-S36

  • 24. Ciuca IM Pop L Tamas L Taban S. Cystic fibrosis liver disease - from diagnosis to risk factors. Rom J Morphol Embryol 2014;55(1):91-5

  • 25. Kozlowska WJ. Lung Function from Infancy to the Preschool Years after Clinical Diagnosis of Cystic Fibrosis. American J of Resp

  • Crit Care Med 2008;178(1):42-49

  • 26. Moran A Dunitz J Nathan B Saeed A Holme B Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence incidence and mortality. Diabetes Care 2009;32:1626 -1631

  • 27. Vanderhelst E. Prevalence and impact on FEV1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with Cystic Fibrosis: A single-center case control study of 165 patients. J Cyst Fibros 2012;11:2-7

  • 28. Da Silva LVRF Ferreira F de A Reis FJC et al. Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact diagnosis and treatment. J Bras Pneumol 2013;39(4):495- 512

  • 29. Bedreag OH Rogobete AF Luca L Neamtu C Dragulescu DM Nartita R Papurica M. Incidence of pathogens infections in a Romanian Intensive Care Unit and sensitivity to antibiotics. A prospective single center study. Acta Medica Marisiensis 2016;62(1):21-26

  • 30. Ratjen G Comes K Paul HG Posselt TO Wagner K. Harms Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 2001;31(1):13-16

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 294 148 12
PDF Downloads 173 105 9